#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Meta-analysis of Efficacy and Safety of Third-Generation Antiseizure Medications in Adjunctive Treatment of Focal Seizures in Adults with Epilepsy

Epilepsy treatment is primarily symptomatic, aimed at reducing seizure frequency. However, more than 50% of patients do not achieve seizure freedom with monotherapy. Below we summarize the results of a meta-analysis comparing the efficacy and safety of third-generation antiseizure medications in the treatment of focal seizures in adults with epilepsy.
Source: Epilepsy 8. 6. 2023

News Options for Modifying and Improving the Efficiency of the HJHS Scoring System

The Hemophilia Joint Health Score (HJHS) is a validated tool for assessing joint health in individuals with hemophilia. Can it be modified to be used more effectively in clinical practice?
Source: Hemophilia with Movement 30. 11. 2020

News Does the type of oral anticoagulant affect heparin dosing during catheter ablation?

During catheter ablation, which patients undergo as part of atrial fibrillation (AF) treatment, current guidelines recommend the administration of heparin without interrupting oral anticoagulant therapy. A recently published analysis evaluated whether the type of oral anticoagulant affects the total dose of heparin administered during the ablation.
Source: Anticoagulant Treatment 22. 3. 2021

News 6-year data from the ECHELON-1 study: How does combining brentuximab vedotin with chemotherapy affect overall survival of previously untreated cHL patients?

At this year's annual congress of the European Hematology Association (EHA), results from the analysis of 6-year data from the international randomized open-label phase III ECHELON-1 study on overall survival of patients with classical Hodgkin lymphoma (cHL) stage III/IV who received a combination of brentuximab vedotin with chemotherapy in the first-line treatment were presented, among other findings.
Source: Hematologic Malignancies 10. 8. 2022

News Practical Two-Point Pharmacokinetic Protocol in Hemophilia A

A recently published study confirmed the practicality of a shortened and simple pharmacokinetic protocol for patients with hemophilia A.
Source: Hemophilia 31. 1. 2022

Journal articles Evolution of chronic lymphocytic leukemia treatment over the past 25 years

Author of the article: T. Papajík, R. Urbanová, P. Turcsányi Source: Transfuze a hematologie dnes | 1/2019 29. 3. 2019

News Monocyte Distribution Width as an Early Indicator of Sepsis in ICU Patients

Authors of a Franco-Spanish study propose using the monocyte distribution width along with leukocyte count as a screening test to refine the early diagnosis of sepsis in intensive care unit (ICU) patients based on their research findings.
Source: Because 9. 4. 2022

News Benefit of Maintenance Therapy with Olaparib in Newly Diagnosed Advanced Ovarian Cancer

The SOLO-1 study evaluated whether the use of the PARP inhibitor olaparib in the maintenance treatment of patients with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer with BRCA 1/2 mutation leads to an improved prognosis for these patients.
Source: Ovarian and Breast Cancer 17. 3. 2020

News The Importance of Early Diagnosis and Treatment of AATD in Preventing Pulmonary Emphysema

Alpha-1 antitrypsin deficiency (AATD) is a risk factor for the development of various diseases, including pulmonary emphysema. Currently, it is significantly underdiagnosed, and the availability of effective treatment is a reason for conducting its screening. The Czech Pneumological and Phthisiological Society ČLS JEP (ČPFS) recommends examining AAT levels in all patients with irreversible obstructive ventilatory disorders of any origin, direct relatives of patients with AATD, and individuals with chronic liver disease of unclear origin. The RAPID-OLE study has shown that treatment of alpha-1 antitrypsin deficiency modifies the course of this disease and underscores the importance of early intervention.
Source: Deficiency of Alpha-1-Antitrypsin 13. 7. 2020

News Incidence and Risk Factors of Community-Acquired Pneumonia in Hematologic Oncologic Patients

Patients with hematologic malignancies are at higher risk of infectious diseases, particularly community-acquired pneumonia, due to immunosuppression. However, recent data providing information on the incidence and risk factors of community-acquired pneumonia in this patient group are quite limited. The aim of the cohort study published by Dutch authors was therefore to supplement the missing recent information on the issue of community-acquired pneumonia in hematologic oncologic patients.
Source: Anti-Infectives 5. 7. 2022

News Post-COVID-19 Patient Care from the Perspective of Experts Across Fields

For many patients with COVID-19, overcoming the acute phase is crucial, but we now know that the disease may not end there. Some patients even manage the acute stage with very mild symptoms, and significant difficulties arise later in the form of 'post-COVID syndrome.' This issue was discussed in detail at a January webinar by leading experts from various fields.
Source: Cough Therapy 19. 3. 2021

News Effectiveness and Safety of Initiating Treatment for Primary Immunodeficiency with Subcutaneously Administered Immunoglobulins –⁠ A Systematic Review of the Literature

The aim of the systematic review of the literature published last year was to evaluate the effectiveness and safety of initiating treatment with subcutaneously administered immunoglobulins (SCIG) in patients with primary immunodeficiency (PID) who had not previously been treated with this modality. There was insufficient data available for such a defined population because SCIGs had typically been introduced into studies only after intravenously administered immunoglobulins (IVIG).
Source: Primary and Secondary Immunodeficiencies 1. 12. 2023

News Diosmin Succeeded in Preventing Ovarian Hyperstimulation Syndrome in Study

In a recently published study, diosmin was evaluated in women undergoing in vitro fertilization (IVF). Attention was focused on its effect in preventing and treating ovarian hyperstimulation syndrome (OHSS).
Source: Venous Insufficiency 28. 5. 2020

News Safety and Efficacy of Combination Therapy for Allergic Rhinitis Compared to Monotherapies and Placebo

Combination therapy of antihistamine and corticosteroid is a promising alternative for patients suffering from seasonal allergic rhinitis. A phase II clinical study aimed to determine the effective dosage, efficiency, and safety of combination therapy compared to monotherapies and placebo.
Source: Life Without Allergic Rhinitis 7. 6. 2022

News Efficacy of Bruton Tyrosine Kinase Inhibitors After Venetoclax Therapy in Patients with CLL

Targeted therapy has changed the treatment approach for chronic lymphocytic leukemia (CLL), showing higher efficacy and safety compared to standard chemoimmunotherapy. Until recently, an important question remained unanswered: whether the administration of Bruton tyrosine kinase inhibitors (BTKi) after previous therapy with the BCL-2 inhibitor venetoclax provides sufficient clinical effect.
Source: Chronic Lymphocytic Leukemia 11. 12. 2020

News EHL preparations have the potential to change the quality of life for people with hemophilia

Within the therapeutic modalities for hemophilia, the current era offers a number of preparations. Newer extended half-life (EHL) replacement therapies can provide hemophiliacs with better protection against bleeding and allow for greater physical activity.
Source: Hemophilia with Movement 27. 10. 2020

Journal articles Immunotherapy in the Treatment of Lung Cancer

Author of the article: O. Fiala, O. Šorejs, M. Pešek, J. Fínek Source: Klinická onkologie | Supplementum3/2017 12. 12. 2017

News Current Recommendations of the Expert Panel on the Management of von Willebrand Disease

Von Willebrand disease (vWD) is a common congenital bleeding disorder. The care of patients with vWD involves significant variability due to bleeding manifestations and treatment options. The new recommendations from 2021 regarding the care of people with vWD are evidence-based and supported by the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation USA (NHF), and the World Federation of Hemophilia (WFH). We bring you a concise summary of the key points.
Source: Von Willebrand Disease 4. 1. 2022

News Invitation to June: ESMO Gastrointestinal Cancers Congress 2024, Munich

Source: Treatment of Gastrointestinal Carcinomas 31. 5. 2024

News Smaller Volume and Faster Infusion Rate of aPCC: What Do Current Data Say About This Modification?

Administering an infusion of activated prothrombin complex concentrate (aPCC) at the standardized rate of 2 U/kg/min can be time-consuming, especially when repeated applications are needed. The authors of the recently published multicenter study cited below focused on the safety and tolerability of reducing the infusion volume by 50% and increasing the infusion rate to 4 and 10 U/kg/min.
Source: Hemophilia 6. 10. 2024

News Estimated Worldwide Prevalence of Population with AAT Deficiency with MZ Alleles

Alpha-1-antitrypsin deficiency (AATD) with the MZ genotype was until recently associated with negligible or low risk for lung and liver tissue damage. However, growing evidence suggests that carriers of MZ alleles are at increased risk of organ damage when exposed to tobacco smoke, polluted air, or hepatotoxic substances. Moreover, according to a global epidemiological study, the prevalence of the MZ genotype is very common, especially among Caucasians in Europe and other continents.
Source: Deficiency of Alpha-1-Antitrypsin 14. 11. 2022

News Repeated Episodes of Respiratory Failure Due to Undiagnosed AAT Deficiency –⁠ Case Report

The case report from authors in Naples shows that alpha-1-antitrypsin deficiency (AATD) should be considered when respiratory symptoms occur at any age. It also illustrates the diagnostic procedure in such cases and confirms the effectiveness of subsequently initiated therapy.
Source: Deficiency of Alpha-1-Antitrypsin 14. 11. 2022

News Patient Evaluation of Durvalumab Treatment Results

The interim analysis results of the PACIFIC study, which monitored the efficacy of durvalumab in the treatment of locally advanced unresectable non-small cell lung cancer (NSCLC), demonstrated a significantly longer progression-free survival (PFS) with this treatment compared to placebo. The following work analyzed one of the secondary objectives of the PACIFIC study −⁠ patient-reported outcomes (PRO).
Source: Lung Cancer 31. 3. 2020

News Clinical Experiences with Reversing Dabigatran with Idarucizumab

Idarucizumab is an effective specific antidote to dabigatran, which very quickly negates its coagulative effects in cases of severe bleeding conditions or emergency surgical procedures. A Danish retrospective study examined clinical experiences with the use of idarucizumab for blocking dabigatran and related clinical outcomes.
Source: Anticoagulant Treatment 9. 12. 2021

News Comparison of Dabigatran and Vitamin K Antagonists in Patients with Atrial Fibrillation in Real-World Practice

The final 3-year results of the GLORIA-AF study conducted in real-world practice with patients newly diagnosed with atrial fibrillation show a lower incidence of major bleeding and lower overall mortality with comparably effective prevention of cerebrovascular accidents and myocardial infarction when administering dabigatran compared to vitamin K antagonists (VKAs).
Source: Anticoagulant Treatment 21. 6. 2022

1 10 11 12 13 14 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#